Skip to content

US · KLRS · BIOTECHNOLOGY

Kalaris Therapeutics Inc (KLRS) intrinsic value and stock valuation

$1.28as of 2026-11-21 · Mkt cap 78.36M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Kalaris Therapeutics Inc DCF and intrinsic value

InvestorsCraft values KLRS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from KLRS’s statements →

Kalaris Therapeutics Inc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Berkeley Heights, NJ 07922 kalaristx.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-43.44M
20182025
Free cash flow
-$-43.18M
20182025
Total equity
$78.8M-25.9% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-46.15M-$-55.26M-$-13.46M-$-14.01M-$-169.82M
Net income-$-43.44M-$-58.77M-$-14.7M-$-15.48M-$-171.96M
EPSd-$-2.84M-$-11.73M-$-3.25M-$-4.65M-$-62.99M
Operating cash flow-$-42.98M-$-67.7M-$-14.13M-$-9.78M-$-106.32M
Capital expenditure-$-200K$0.00$0.00$0.00-$-30K
Free cash flow-$-43.18M-$-67.7M-$-14.13M-$-9.78M-$-106.34M
Total assets$121.7M$118.6M$3.33M$3.9M$286.6M
Total debt$1.45M$0.00$0.00$3.25M$30.1M
Net debt-$-96.61M-$-118.29M-$-3.17M$190K-$-171.59M
Total equity$78.8M$113.3M-$-45.02M-$-30.27M$225.3M
Cash and short-term investments$118M$118.3M$3.17M$3.06M$248.1M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$10K$0.00$0.00$0.00$1.12M
Gross profit-$-10K$0.00$0.00$0.00-$-1.12M
Research and development expenses$30.8M$12.3M$11.7M$11.8M$119.6M
Selling, general and administrative expenses$15.4M$42.9M$1.76M$2.24M$49.1M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$46.1M$55.3M$13.5M$14M$168.7M
Cost and expenses$46.2M$55.3M$13.5M$14M$169.8M
Interest income$0.00$5.49M$0.00$0.00$1.31M
Interest expense$1.44M$0.00$690K$230K$0.00
Depreciation and amortization$10K$0.00$0.00$0.00$1.12M
Ebitda-$-41.98M-$-58.77M-$-14.01M-$-15.25M-$-169.84M
Operating income-$-46.15M-$-55.26M-$-13.46M-$-14.01M-$-169.82M
Total other income/expenses, net$2.71M-$-3.51M-$-1.24M-$-1.48M-$-1.14M
Income before tax-$-43.44M-$-58.77M-$-14.7M-$-15.48M-$-170.96M
Income tax expense$0.00$0.00$0.00$0.00$1.01M
Net income-$-43.44M-$-58.77M-$-14.7M-$-15.48M-$-171.96M
Weighted average shares outstanding$15.3M$5.01M$4.52M$3.33M$2.73M
Weighted average diluted shares outstanding$15.3M$5.01M$4.52M$3.33M$2.73M
Balance sheet
20252024202320222021
Cash and short-term investments$118M$118.3M$3.17M$3.06M$248.1M
Net receivables$0.00$0.00$0.00$0.00$50K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$118.8M$118.6M$3.33M$3.9M$253.4M
Property, plant and equipment, net$1.48M$0.00$0.00$0.00$31.3M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$500K$0.00$0.00$0.00$850K
Total non-current assets$2.93M$0.00$0.00$0.00$33.3M
Total assets$121.7M$118.6M$3.33M$3.9M$286.6M
Accounts payable$1.28M$250K$2.36M$2.76M$8.36M
Short-term debt$320K$0.00$0.00$0.00$6.59M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$9.71M$5.24M$3.94M$5.69M$37.9M
Long-term debt$1.13M$0.00$0.00$3.25M$23.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$33.2M$0.00$44.4M$28.5M$23.5M
Capital lease obligations$1.13M$0.00$0.00$0.00$23.5M
Total liabilities$42.9M$5.24M$48.4M$34.2M$61.3M
Common stock$0.00$0.00$0.00$0.00$10K
Retained earnings-$-160M-$-714.96M-$-47.39M-$-32.7M-$-297.06M
Accumulated other comprehensive income (loss)$10K-$-140K$0.00$0.00-$-150K
Total equity$78.8M$113.3M-$-45.02M-$-30.27M$225.3M
Total investments$20.4M$0.00$0.00$0.00$47.3M
Total debt$1.45M$0.00$0.00$3.25M$30.1M
Net debt-$-96.61M-$-118.29M-$-3.17M$190K-$-171.59M
Cash flow statement
20252024202320222021
Net income-$-43.44M-$-58.77M-$-14.7M-$-15.48M-$-171.96M
Depreciation and amortization$10K$0.00$0.00$0.00$1.12M
Stock-based compensation$0.00$0.00$150K$270K$0.00
Change in working capital$3.43M-$-25.3M-$-1.09M$3.4M$19.4M
Accounts receivable$0.00$210K$0.00$0.00$400K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-90K-$-28.86M-$-400K$1.83M$20.3M
Net cash provided by operating activities-$-42.98M-$-67.7M-$-14.13M-$-9.78M-$-106.32M
Investments in property, plant and equipment-$-200K$0.00$0.00$0.00-$-30K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-19.72M$95M$0.00$0.00$186M
Common stock issued$50M$20K$0.00$0.00$230K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$159.6M$20K$14.2M$12.8M$230K
Net change in cash-$-20.23M$28.2M$110K$3M$79M
Cash at end of period$98.1M$118.3M$3.17M$3.06M$201.7M
Operating cash flow-$-42.98M-$-67.7M-$-14.13M-$-9.78M-$-106.32M
Capital expenditure-$-200K$0.00$0.00$0.00-$-30K
Free cash flow-$-43.18M-$-67.7M-$-14.13M-$-9.78M-$-106.34M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Kalaris Therapeutics Inc

        Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.

        CEO
        Andrew Oxtoby
        Employees
        20
        Beta
        0.19

        Explore

        Frequently asked questions

        What is the intrinsic value of Kalaris Therapeutics Inc (KLRS)?

        InvestorsCraft does not currently publish an intrinsic value for KLRS. How the IC value is calculated.

        Is KLRS undervalued?

        InvestorsCraft does not publish an undervaluation signal for KLRS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.